

Supplementary Materials: New Iridoid Glucosides from *Caryopteris incana* (Thunb.) Miq. and Their α -Glucosidase Inhibitory Activities

Xu-Dong Mao, Gui-Xin Chou, Sen-Miao Zhao and Cheng-Gang Zhang

Contents of Supplementary Information.

No.	Contents	Pages
1.	Figure S1. ^{13}C NMR spectrum of caryocanoside B (1) in MeOD (100MHz).	2
2.	Figure S2. ^1H NMR spectrum of caryocanoside B (1) in MeOD (400MHz).	3
3.	Figure S3. HSQC spectrum of caryocanoside B (1) in MeOD.	4
4.	Figure S4. HMBC spectrum of caryocanoside B (1) in MeOD.	5
5.	Figure S5. NOESY spectrum of caryocanoside B (1) in MeOD.	6
6.	Figure S6. ^1H - ^1H COSY spectrum of caryocanoside B (1) in MeOD.	7
7.	Figure S7. HRESIMS spectrum of caryocanoside B (1).	8
8.	Figure S8. IR spectrum of caryocanoside B (1).	9
9.	Figure S9. ^{13}C NMR spectrum of 5-hydroxy-2''-O-caffeoylelcaryocanoside B (2) in MeOD (100MHz).	10
10.	Figure S10. ^1H NMR spectrum of 5-hydroxy-2''-O-caffeoylelcaryocanoside B (2) in MeOD (400MHz).	11
11.	Figure S11. HSQC spectrum of 5-hydroxy-2''-O-caffeoylelcaryocanoside B (2) in MeOD.	12
12.	Figure S12. HMBC spectrum of 5-hydroxy-2''-O-caffeoylelcaryocanoside B (2) in MeOD.	13
13.	Figure S13. NOESY spectrum of 5-hydroxy-2''-O-caffeoylelcaryocanoside B (2) in MeOD.	14
14.	Figure S14. ^1H - ^1H COSY spectrum of 5-hydroxy-2''-O-caffeoylelcaryocanoside B (2) in MeOD.	15
15.	Figure S15. HRESIMS spectrum of 5-hydroxy-2''-O-caffeoylelcaryocanoside B (2).	16
16.	Figure S16. IR spectrum of 5-hydroxy-2''-O-caffeoylelcaryocanoside B (2).	17
17.	Figure S17. ^{13}C NMR spectrum of 2''-O-(E)-p-coumaroyl caryocanoside B (3) in MeOD (150MHz).	18
18.	Figure S18. ^1H NMR spectrum of 2''-O-(E)-p-coumaroyl caryocanoside B (3) in MeOD (600MHz).	19
19.	Figure S19. HSQC spectrum of 2''-O-(E)-p-coumaroyl caryocanoside B (3) in MeOD.	20
20.	Figure S20. HMBC spectrum of 2''-O-(E)-p-coumaroyl caryocanoside B (3) in MeOD	21
21.	Figure S21. NOESY spectrum of 2''-O-(E)-p-coumaroyl caryocanoside B (3) in MeOD.	22
22.	Figure S22. ^1H - ^1H COSY spectrum of 2''-O-(E)-p-coumaroyl caryocanoside B (3) in MeOD.	23
23.	Figure S23. HRESIMS spectrum of 2''-O-(E)-p-coumaroyl caryocanoside B (3).	24
24.	Figure S24. IR spectrum of 2''-O-(E)-p-coumaroyl caryocanoside B (3).	25
25.	Figure S25. ^{13}C NMR spectrum of 2''-O-(Z)-p-coumaroyl caryocanoside B (4) in MeOD (100MHz).	25
26.	Figure S26. ^1H NMR spectrum of 2''-O-(Z)-p-coumaroyl caryocanoside B (4) in MeOD (400MHz).	26
27.	Figure S27. HSQC spectrum of 2''-O-(Z)-p-coumaroyl caryocanoside B (4) in MeOD.	27
28.	Figure S28. HMBC spectrum of 2''-O-(Z)-p-coumaroyl caryocanoside B (4) in MeOD.	27
29.	Figure S29. NOESY spectrum of 2''-O-(Z)-p-coumaroyl caryocanoside B (4) in MeOD.	28
30.	Figure S30. ^1H - ^1H COSY spectrum of 2''-O-(Z)-p-coumaroyl caryocanoside B (4) in MeOD.	28
31.	Figure S31. HRESIMS spectrum of 2''-O-(Z)-p-coumaroyl caryocanoside B (4).	29
32.	Figure S32. IR spectrum of 2''-O-(Z)-p-coumaroyl caryocanoside B (4).	29
33.	Figure S33. ^{13}C NMR spectrum of 2'-O-(E)-p-coumaroyl asystasioside A (5) in MeOD (150MHz).	30
34.	Figure S34. ^1H NMR spectrum of 2'-O-(E)-p-coumaroyl asystasioside A (5) in MeOD (600MHz).	30
35.	Figure S35. HSQC spectrum of 2'-O-(E)-p-coumaroyl asystasioside A (5) in MeOD.	31
36.	Figure S36. HMBC spectrum of 2'-O-(E)-p-coumaroyl asystasioside A (5) in MeOD.	32
37.	Figure S37. NOESY spectrum of 2'-O-(E)-p-coumaroyl asystasioside A (5) in MeOD.	33
38.	Figure S38. ^1H - ^1H COSY spectrum of 2'-O-(E)-p-coumaroyl asystasioside A (5) in MeOD.	34
38.	Figure S39. HRESIMS spectrum of 2'-O-(E)-p-coumaroyl asystasioside A (5).	35
40.	Figure S40. IR spectrum of 2'-O-(E)-p-coumaroyl asystasioside A (5).	36
41.	Figure S41. chemical constitution of compound 1–5.	37
42.	Figure S42. chemical constitution of compound 6–11.	38
43.	Table S1 in vitro α -glucosidase inhibitory activity of compounds 1–11.	38




Figure S1. ^{13}C NMR spectrum of caryocanose B (**1**) in MeOD (100MHz).





Figure S2. ¹H NMR spectrum of caryocanatoside B (1) in MeOD (400 MHz).







Figure S3. Heteronuclear single quantum correlation (HSQC) spectrum of caryocanose B (**1**) in MeOD.





Figure S4. Heteronuclear multiple bond correlation (HMBC) spectrum of caryocanatoside B (**1**) in MeOD.





Figure S5. Nuclear Overhauser effect spectroscopy (NOESY) spectrum of caryocanatoside B (**1**) in MeOD.





Figure S6. ^1H - ^1H correlation spectroscopy (^1H - ^1H COSY) spectrum of caryocanoside B (**1**) in MeOD.




Figure S7. High resolution electrospray ionization mass spectroscopy (HRESIMS) spectrum of caryocanose B (1).





Figure S8. Infrared (IR) spectrum of caryocanoseide B (**1**).





Figure S9. ¹³C NMR spectrum of 5-hydroxy-2'''-O-caffeoylcaryocanose B (**2**) in MeOD (100 MHz).




Figure S10. ¹H NMR spectrum of 5-hydroxy-2'''-O-caffeoylcaryocanose B (2) in MeOD (400 MHz).




Figure S11. HSQC spectrum of 5-hydroxy-2''-O-caffeoylcaryocanose B (**2**) in MeOD.





Figure S12. HMBC spectrum of 5-hydroxy-2''-O-caffeoylcaryocanose B (**2**) in MeOD.





Figure S13. NOESY spectrum of 5-hydroxy-2'''-O-caffeoylcaryocanose B (**2**) in MeOD.





Figure S14. ^1H - ^1H COSY spectrum of 5-hydroxy-2'''-O-caffeoylcaryocanose B (**2**) in MeOD.




Figure S15. HRESIMS spectrum of 5-hydroxy-2''-O-caffeoylelcaryocanose B (2).




Figure S16. IR spectrum of 5-hydroxy-2''-O-caffeoylcaryocanatoside B (2).





Figure S17. ¹³C NMR spectrum of 2''-O-(*E*)-*p*-coumaroyl caryocanatoside B (3) in MeOD (150 MHz).





Figure S18. ¹H NMR spectrum of 2''-O-(*E*)-*p*-coumaroyl caryocanatoside B (3) in MeOD (600 MHz).





Figure S19. HSQC spectrum of 2''-O-(E)-p-coumaroyl caryocanatoside B (**3**) in MeOD.





Figure S20. HMBC spectrum of 2'''-O-(*E*)-*p*-coumaroyl caryocanatoside B (**3**) in MeOD.





Figure S21. NOESY spectrum of 2''-O-(E)-*p*-coumaroyl caryocanatoside B (**3**) in MeOD.





Figure S22. ^1H - ^1H COSY spectrum of $2''\text{-O-(E)-}p\text{-coumaroyl caryocanatoside B (3)}$ in MeOD .






Figure S23. HRESIMS spectrum of 2''-(E)-p-coumaroyl caryocanatoside B (3).





Figure S24. IR spectrum of 2'''-O-(E)-p-coumaroyl caryocanatoside B (3).





Figure S25. ¹³C NMR spectrum of 2'''-O-(Z)-p-coumaroyl caryocanatoside B (4) in MeOD (100 MHz).




Figure S26. ¹H NMR spectrum of 2''-O-(Z)-*p*-coumaroyl caryocanatoside B (4) in MeOD (400 MHz).




Figure S27. HSQC spectrum of 2''-O-(Z)-p-coumaroyl caryocanatoside B (4) in MeOD.




Figure S28. HMBC spectrum of 2''-O-(Z)-p-coumaroyl caryocanatoside B (4) in MeOD.




Figure S29. NOESY spectrum of 2'''-O-(Z)-*p*-coumaroyl caryocanose B (**4**) in MeOD.




Figure S30. ¹H-¹H COSY spectrum of 2'''-O-(Z)-*p*-coumaroyl caryocanose B (**4**) in MeOD.




Figure S31. HRESIMS spectrum of 2''-O-(Z)-*p*-coumaroyl caryocanatoside B (4)




Figure S32. IR spectrum of 2''-O-(Z)-*p*-coumaroyl caryocanatoside B (4).




Figure S33. ^{13}C NMR spectrum of 2'-O-(*E*)-*p*-coumaroyl asystasioside A (5) in MeOD (150 MHz).




Figure S34. ^1H NMR spectrum of 2'-O-(*E*)-*p*-coumaroyl asystasioside A (5) in MeOD (600 MHz).





Figure S35. HSQC spectrum of 2'-O-(E)-*p*-coumaroyl asystasioside A (**5**) in MeOD.





Figure S36. HMBC spectrum of 2'-O-(E)-*p*-coumaroyl asystasioside A (**5**) in MeOD.





Figure S37. NOESY spectrum of 2'-O-(E)-p-coumaroyl asystasioside A (5) in MeOD.





Figure S38. ^1H - ^1H COSY spectrum of 2'-*O*-(*E*)-*p*-coumaroyl asystasioside A (**5**) in MeOD.




Figure S39. HRESIMS spectrum of 2'-*O*-(*E*)-*p*-coumaroyl asystasioside A (5).





Figure S40. IR spectrum of 2'-O-(E)-p-coumaroyl asystasioside A (5).





Figure S41. Chemical constitution of compounds **1**–**5**.

**Figure S42.** Chemical constitution of compounds **6–11**.**Table S1.** In vitro α -glucosidase inhibitory activity of compounds **1–11**.

Compounds	IC_{50}	Compounds	IC_{50}
1	>5.0	7	1.38 ± 0.27
2	>5.0	8	0.82 ± 0.15
3	>5.0	9	>5.0
4	0.38 ± 0.015	10	0.33 ± 0.06
5	3.35 ± 0.12	11	>5.0
6	1.89 ± 0.7	acarbose	3.49 ± 0.15